1. Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer
   Donna M. Graham et al, 2016, Current Colorectal Cancer Reports CrossRef
2. Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
   Abdullah Alhusaini et al, 2021, Biomedicines CrossRef
3. Preclinical Chemosensitization by PARP Inhibitors
   David R. Shalinsky et al, 2015, PARP Inhibitors for Cancer Therapy CrossRef
4. Influence of hypoxia‑related genetic polymorphisms on the prognosis of patients with metastatic gastric cancer treated with EOF
   Wenbo Tang et al, 2017, Oncology Letters CrossRef
5. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics
   Philip R. Cohen et al, 2016, Oncotarget CrossRef
6. DNA damage response and repair in colorectal cancer: Defects, regulation and therapeutic implications
   Mohammad Mirza-Aghazadeh-Attari et al, 2018, DNA Repair CrossRef
7. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide
   Lucio Tentori et al, 2014, BMC Cancer CrossRef
8. Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers
   Cinzia Tesauro et al, 2014, Journal of Experimental & Clinical Cancer Research CrossRef
9. Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress
   Raúl Ortíz et al, 2021, Cancers CrossRef